GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » 3-Year FCF Growth Rate
Switch to:

Biogen (BUE:BIIB) 3-Year FCF Growth Rate

: -38.90% (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's Free Cash Flow per Share for the three months ended in Mar. 2023 was ARS522.04.

During the past 12 months, Biogen's average Free Cash Flow per Share Growth Rate was -47.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -38.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Biogen was 181.50% per year. The lowest was -124.10% per year. And the median was 22.80% per year.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen 3-Year FCF Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Biogen's 3-Year FCF Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 3-Year FCF Growth Rate's extreme value range as defined by GuruFocus.



Biogen 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Biogen  (BUE:BIIB) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Biogen 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Biogen's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines

Other Sources